Collectively, the present study demonstrated that baricitinib, a selective inhibitor for JAK1 and JAK2, could mitigate autoimmune features in lupus-prone mice by suppressing eccentric B cell activation and recovering structural injuries of podocytes. This evidence concerns the gene JAK1 and systemic lupus erythematosus.